Table 4.
Associations of urine NGAL and KIM-1 with 2-year and 10-year all-cause mortality
| Mortality events |
Model 1a HR (95% CI) |
Model 2b HR (95% CI) |
Model 3c HR (95% CI) |
|
|---|---|---|---|---|
| NGAL | ||||
| Mortality at 2-year follow-up | ||||
| NGAL T1 (reference) | 39/490 (8%) | |||
| NGAL T2 versus T1 | 44/491 (9%) | 1.39 (0.89, 2.17) | 1.07 (0.68, 1.69) | 1.03 (0.65, 1.62) |
| NGAL T3 versus T1 | 67/491 (14%) | 2.45 (1.61, 3.72) | 1.73 (1.12, 2.68) | 1.60 (1.03, 2.49) |
| NGAL (per doubling) | 150/1472 (10%) | 1.20 (1.11, 1.29) | 1.13 (1.05, 1.23) | 1.12 (1.03, 1.21) |
| Mortality entire follow-up period | ||||
| NGAL T1 (reference) | 252/490 (51%) | |||
| NGAL T2 versus T1 | 285/491 (58%) | 1.33 (1.12, 1.58) | 1.17 (0.98, 1.40) | 1.12 (0.93, 1.33) |
| NGAL T3 versus T1 | 282/491 (57%) | 1.45 (1.21, 1.74) | 1.20 (1.00, 1.45) | 1.13 (0.94, 1.37) |
| NGAL (per doubling) | 819/1472 (56%) | 1.09 (1.05, 1.13) | 1.05 (1.02, 1.09) | 1.04 (1.00, 1.08) |
| KIM-1 | ||||
|---|---|---|---|---|
| Mortality at 2-year follow-up | ||||
| KIM1 T1 (reference) | 41/490 (8%) | |||
| KIM1 T2 versus T1 | 48/491 (10%) | 1.27 (0.82, 1.98) | 1.09 (0.69, 1.72) | 1.05 (0.67, 1.67) |
| KIM1 T3 versus T1 | 61/490 (12%) | 2.38 (1.52, 3.73) | 1.58 (0.97, 2.57) | 1.62 (0.99, 2.66) |
| KIM-1 (per doubling) | 150/1471 (10%) | 1.40 (1.21, 1.63) | 1.22 (1.03, 1.44) | 1.23 (1.04, 1.47) |
| Mortality entire follow-up period | ||||
| KIM1 T1 (reference) | 260/490 (53%) | |||
| KIM1 T2 versus T1 | 277/491 (56%) | 1.21 (1.01, 1.44) | 1.05 (0.87, 1.26) | 1.04 (0.87, 1.25) |
| KIM1 T3 versus T1 | 281/490 (57%) | 1.58 (1.30, 1.92) | 1.19 (0.96, 1.47) | 1.23 (0.99, 1.51) |
| KIM-1 (per doubling) | 818/1471 (56%) | 1.21 (1.13, 1.29) | 1.09 (1.01, 1.17) | 1.10 (1.03, 1.19) |
CI, confidence interval; HR, hazard ratio; KIM-1, kidney injury molecule−1; NGAL, neutrophil gelatinase−associated lipocalin; T1, tertile 1; T2, tertile 2; T3, tertile 3.
a
Model 1: Age, sex, race, socioeconomic status, urine creatinine.
b
Model 2: 1+ diabetes, systolic blood pressure, diastolic blood pressure, hypertension, smoking, body mass index, alcohol use, albumin-to-creatinine ratio, C-reactive protein.
c
Model 3: 2+ eGFRcr-cys.